Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Frequently asked questions
What sector does Telomir Pharmaceuticals, Inc. Common Stock (TELO) operate in?
Telomir Pharmaceuticals, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Telomir Pharmaceuticals, Inc. Common Stock (TELO) current stock price?
As of the latest data, Telomir Pharmaceuticals, Inc. Common Stock stock price is $1.00, with a previous close of $0.98. Telomir Pharmaceuticals, Inc. Common Stock gained $0.02 in the last trading session, representing a 2.4% increase.
What is Telomir Pharmaceuticals, Inc. Common Stock (TELO) current market capitalization?
Telomir Pharmaceuticals, Inc. Common Stock market cap is approximately 68.67 million.
What is Telomir Pharmaceuticals, Inc. Common Stock (TELO) Earnings Per Share (EPS)?
The trailing EPS is -$1.09, and the forward EPS is -$0.28.
What is Telomir Pharmaceuticals, Inc. Common Stock (TELO) EBITDA?
Telomir Pharmaceuticals, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.72 million.
Does Telomir Pharmaceuticals, Inc. Common Stock (TELO) pay dividends?
No. Telomir Pharmaceuticals, Inc. Common Stock does not pay a dividend.
When is Telomir Pharmaceuticals, Inc. Common Stock (TELO) next earnings report?
Telomir Pharmaceuticals, Inc. Common Stock is expected to release its next earnings report on September 30, 2026.
What is Telomir Pharmaceuticals, Inc. Common Stock (TELO) beta (volatility) score?
Telomir Pharmaceuticals, Inc. Common Stock has a beta of -0.247, indicating lower volatility than the overall market.
